[Skip to Content]
[Skip to Content Landing]
April 1995

Pregnancy Outcome After Periconceptional and First-Trimester Exposure to Methoxsalen Photochemotherapy

Author Affiliations

National Institute of Public Health and Environmental Protection 3720 BA Bilthoven, the Netherlands

Paris, France

Lyon, France

Rome, Italy

Thessaloniki, Greece

Arch Dermatol. 1995;131(4):492-493. doi:10.1001/archderm.1995.01690160122026

Recently, two studies have been published in the ARCHIVES on psoralen plus UVA (PUVA) treatment and the outcome of pregnancy.1,2 The European Network of Teratology Information Services (ENTIS) has identified 41 cases of PUVA treatment around conception and/or during pregnancy, where follow-up had been initiated. These cases are reported herein. Teratology Information Services (TIS) provides information about reproductive toxicity, especially the teratogenic effects of drugs and other exogenous agents, and collects and evaluates prospective follow-up data on the outcome of pregnancy following exposure to those agents. The methodology is described elsewhere.3,4

Data were collected on two occasions, first, at the time of the inquiry (usually by telephone) to TIS (intake data) and, second, by means of a follow-up form, which was sent to the physician in the month after the expected delivery (moment of follow-up).

Thirty-two women underwent treatment with PUVA prior to conception and during pregnancy. Another

First Page Preview View Large
First page PDF preview
First page PDF preview